PLEASANTON, Calif., Nov. 20, 2023 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) begins taking orders for the Evie Ring, the smart ring designed specifically for women, today at 12 pm EST. An innovative and comfortable form factor, a focus on helping women track and analyze their health and fitness, and an emphasis on big-picture data interpretation rather than individual activity scores set Evie apart from other wearables, providing a valuable new tool for women seeking to take control of their health.
Built from the ground up using research that uncovers the differences between men's and women's biomarkers as well as interviews with more than 1,000 women about their health and wellness needs, Evie monitors key health and wellness metrics. Biometric sensors track sleep stages and duration, resting heart rate, heart rate variability, blood oxygen saturation (SpO2), respiration rate, skin temperature trends, steps, active minutes, and calorie burn; while users log information ranging from mood and menstrual symptoms, which enables the estimation of periods and ovulation, to illness, stress and alcohol consumption.
These core functions are integrated into a smart ring and companion app that break new ground in the wearable space. Unique features include:
Evie also includes a Spot Check feature enabling users to measure their heart rate and blood oxygen levels at any time, day or night. This is a useful function that can help users who aren't feeling well determine whether to consult with their healthcare providers.
The ring has 4+ days of battery life, and recharges in just 60 minutes. Additionally, Evie comes with a portable charging case that holds 10+ ring charges so users can charge their ring from anywhere and at any time.
The Evie Ring is available exclusively through www.eviering.com in gold, rose gold, and silver finishes and in sizes 5-12 with a complimentary sizing kit for those who don't know their ring size. It costs $269 with no subscription fees. Ring orders will ship January 2024.
About Movano Health
Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health is developing a suite of purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices. Featuring modern form factors, Movano Health's devices capture a comprehensive picture of a person's vital health information and uniquely translate the data into personalized and intelligent insights that empower consumers to live healthier and more balanced lives. Movano Health's end-to-end solutions will soon enable consumers and their healthcare professionals to utilize daily medical-grade data as a tool to proactively monitor and manage health outcomes. For more information on Movano Health, visit https://movanohealth.com/.
Forward Looking Statements
This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding anticipated FDA clearance for the Evie Ring; expected future operating results; product development and features, product releases, clinical trial, and regulatory initiatives; our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Last Trade: | US$5.32 |
Daily Change: | 2.21 71.06 |
Daily Volume: | 25,857 |
Market Cap: | US$35.250M |
December 02, 2024 November 07, 2024 September 03, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB